Recent Advances in the Early Intervention in Schizophrenia: Future Direction from Preclinical Findings

@article{Hashimoto2019RecentAI,
  title={Recent Advances in the Early Intervention in Schizophrenia: Future Direction from Preclinical Findings},
  author={Kenji Hashimoto},
  journal={Current Psychiatry Reports},
  year={2019},
  volume={21},
  pages={1-9}
}
  • K. Hashimoto
  • Published 5 July 2019
  • Medicine, Psychology
  • Current Psychiatry Reports
Purpose of ReviewIn the past decade, there has been increasing interest in the potential benefit of early intervention in schizophrenia. Patients with schizophrenia show cognitive impairment for several years preceding the onset of psychosis. The author discusses the recent topics on prevention of schizophrenia.Recent FindingsPreclinical findings suggest that maternal immune activation (MIA) produces cognitive deficits as a prodromal symptom in juvenile offspring in rodents. Treatment with anti… 
D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?
TLDR
Preclinical and clinical studies with D-serine indicate that it may be effective in reducing cognitive dysfunction and may be a biomarker for antidepressant response to ketamine.
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
TLDR
This systematic review addresses with a direct and reverse translational perspective the efficacy of D-amino acids, including D-serine, D-aspartate, and D-alanine, in poor responders of schizophrenia, together with other emerging molecules.
Supplementation of PQQ from pregnancy prevents MK-801-induced schizophrenia-like behaviors in mice.
TLDR
It is suggested that PQQ supplementation from pregnancy or postpartum could prevent some schizophrenia-like behaviors induced by MK-801 in mice, and the potential usage of dietary supplement of PQZ in preventing or alleviating symptoms associated with schizophrenia is supported.
Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study.
TLDR
Amisulpride is effective in the treatment of schizophrenia and improving depression symptoms, and the improvement of depression symptoms has no significant predictive effect on the remission of schizophrenia symptoms.
Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia
TLDR
The role and mutual interactions of oxidative damage and impaired glucose metabolism as key factors affecting metabolic complications in schizophrenia are summarized to provide a premise for novel potential therapeutic targets that will delay not only the onset of first symptoms but also the progression of schizophrenia and its complications.
Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
TLDR
Clinical and preclinical studies on schizophrenia and ASD investigating the behavioral, molecular, and functional effects of chronic treatment with CBD (and with cannabidivarin for ASD) during neurodevelopment point to CBD's beneficial potential for the progression of these disorders supporting further investigations to strengthen its use.
Mechanisms of action of fluvoxamine for COVID-19: a historical review
TLDR
A possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders and schizophrenia in offspring is discussed and fluvoxamine is the most attractive drug for mild to moderate subjects with CO VID-19.
The Nrf2 pathway in psychiatric disorders: pathophysiological role and potential targeting
TLDR
The role of Nrf2 pathway and its modulators in psychiatric disorders is explored to find immense potential opportunities for these modulators to become a novel therapeutic option.
...
...

References

SHOWING 1-10 OF 97 REFERENCES
Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation
TLDR
This study shows that supplementing offspring with D-serine during juvenile and adolescent stages could prevent the onset of psychosis in adulthood, after MIA, and therefore, early intervention in high-risk subjects may prevent the occurrence of psychosis.
Intake of 7,8-Dihydroxyflavone During Juvenile and Adolescent Stages Prevents Onset of Psychosis in Adult Offspring After Maternal Immune Activation
TLDR
It is found that the juvenile offspring of poly(I:C)-treated mice showed cognitive deficits, as well as reduced BDNF-TrkB signaling in the prefrontal cortex (PFC), and intervention by a TrkB agonist in subjects with ultra-high risk for psychosis may reduce the risk of subsequent transition to schizophrenia.
D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?
TLDR
Preclinical and clinical studies with D-serine indicate that it may be effective in reducing cognitive dysfunction and may be a biomarker for antidepressant response to ketamine.
Microglial activation and progressive brain changes in schizophrenia
TLDR
Evidence for microglial dysfunction in schizophrenia is reviewed from both neuroimaging and neuropathological data, with a specific focus on studies examining microglia activation in relation to the pathology of grey and white matter.
Increased Levels of C1q in the Prefrontal Cortex of Adult Offspring after Maternal Immune Activation: Prevention by 7,8-Dihydroxyflavone
  • Mei Han, Ji-chun Zhang, K. Hashimoto
  • Biology, Medicine
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2017
TLDR
It is likely that increased C1q expression in the frontal cortex may play a role in the behavioral abnormalities of adult offspring after MIA and supplementation with a TrkB agonist such as 7,8-DHF during the prodromal stage may have prophylactic effects on the behavior abnormalities after MIA.
PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia
TLDR
The patient cohorts in this study do not substantiate the assumption of microglial activation in schizophrenia as a regular and defining feature, as measured by 11C-(R)-PK11195 BPND, and no correlations with regional gray matter, peripheral cytokine levels or clinical symptoms were detected.
Targeting of NMDA receptors in new treatments for schizophrenia
  • K. Hashimoto
  • Psychology, Medicine
    Expert opinion on therapeutic targets
  • 2014
TLDR
Given the NMDA receptor hypothesis of schizophrenia, the glycine modulatory site on NMDA receptors is the most attractive therapeutic target for this disease, and both the kynurenine pathway and cystine-glutamate antiporter represent credible potential therapeutic targets for schizophrenia.
Dietary glucoraphanin prevents the onset of psychosis in the adult offspring after maternal immune activation
TLDR
It is demonstrated that dietary intake of glucoraphanin (GF), the precursor of a natural antioxidant sulforaphane, during juvenile and adolescent stages prevented cognitive deficits and loss of parvalbumin (PV) immunoreactivity in the medial prefrontal cortex of adult offspring after MIA.
Schizophrenia: Basic and Clinical.
  • J. Coyle
  • Psychology, Medicine
    Advances in neurobiology
  • 2017
TLDR
Pharmacologic challenge studies, postmortem analyses and a recent sufficiently powered genome-wide association study and copy number variant studies provide compelling evidence that NMDA receptor hypofunction is an important pathophsysiologic feature of schizophrenia.
...
...